Tolvaptan improves the diurnal blood pressure profile in patients with hypertension and autosomal-dominant polycystic kidney disease
American Journal of Hypertension · 01.08.2026 · 39 (8) · 1021-1029
DOI: 10.1093/ajh/hpag035 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hypertension, online erschienen am 28.04.2026. Verfasst von Masaaki Hanaoka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Kohsaikai Kamioooka Jinsei Clinic, Yokohama, Japan. Hauptthemen laut MEDLINE: Tolvaptan, Polycystic Kidney, Autosomal Dominant, Blood Pressure, Hypertension. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Yokohama Foundation for the Advancement of Medical Science, Uehara Memorial Foundation, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Autosomal-dominant polycystic kidney disease (ADPKD) is a genetic disorder frequently associated with non-dipper hypertension, with tolvaptan being the only currently approved treatment. However, the effects of tolvaptan on blood pressure (BP) in patients with ADPKD and hypertension remain unclear.
Methods
This retrospective study examined the effect of tolvaptan on 24-h ambulatory BP monitoring parameters. Changes in ambulatory BP-related parameters, including annual rate of change in total kidney volume (TKV), were assessed in 23 patients with ADPKD and hypertension before and after initiating tolvaptan.
Results
After initiation of tolvaptan, nocturnal systolic and diastolic BP dipping rates increased significantly, with systolic dipping rising from 9.61% to 14.0% (Δ + 4.39%; P = .014) and diastolic dipping from 10.48% to 14.66% (Δ + 4.18%; P = .023). The prevalence of a non-dipper BP profile decreased from 57% at baseline to 29% after treatment (P = .0339). In addition, the annual growth rate of TKV decreased from 13.6% to 1.61% (P < .0001), and the eGFR slope improved from −4.46 to −2.26 mL/min/1.73 m2/year (P = .0431).
Conclusions
Tolvaptan treatment was associated with improvements in nocturnal BP decline and diurnal BP patterns in patients with hypertension and ADPKD. In addition, a reduced rate of TKV growth and a slower decline in eGFR were observed. These findings provide further insight into the potential hemodynamic and renal effects of tolvaptan in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kohsaikai Kamioooka Jinsei Clinic, Yokohama, Japan.
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- Department of Nephrology and Hypertension, Yokohama Minami Kyosai Hospital, Kanagawa, Japan.
- Department of Nephrology and Hypertension, Yokohama City University Medical Center, Yokohama, Japan.
ORCID-Profile: Hiromichi Wakui, Kouichi Tamura
Förderung
- Yokohama Foundation for the Advancement of Medical Science
- Uehara Memorial Foundation
- Japan Society for the Promotion of Science
- Japan Kidney Association-Nippon Boehringer Ingelheim Joint Research Program
- Japanese Association of Dialysis Physicians
- Salt Science Research Foundation
- Strategic Research Project of Yokohama City University
- Moriya Scholarship Foundation
Zitieren
APA
Hanaoka, M., Wakui, H., Kanai, D., Kinguchi, S., Azushima, K., Ohnishi, T., & Tamura, K. (2026). Tolvaptan improves the diurnal blood pressure profile in patients with hypertension and autosomal-dominant polycystic kidney disease. American Journal of Hypertension, 39(8), 1021-1029. https://doi.org/10.1093/ajh/hpag035
Vancouver
Hanaoka M, Wakui H, Kanai D, Kinguchi S, Azushima K, Ohnishi T, et al. Tolvaptan improves the diurnal blood pressure profile in patients with hypertension and autosomal-dominant polycystic kidney disease. American Journal of Hypertension. 2026;39(8):1021-1029. doi:10.1093/ajh/hpag035
BibTeX
@article{Hanaoka2026,
author = {Hanaoka, Masaaki and Wakui, Hiromichi and Kanai, Daisuke and Kinguchi, Sho and Azushima, Kengo and Ohnishi, Toshimasa and Tamura, Kouichi},
title = {Tolvaptan improves the diurnal blood pressure profile in patients with hypertension and autosomal-dominant polycystic kidney disease},
journal = {American Journal of Hypertension},
year = {2026},
volume = {39},
number = {8},
pages = {1021--1029},
doi = {10.1093/ajh/hpag035}
}
EUVIMED